吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血
液学不良反应观察
陈芳;姜雪秋;许一清;冯国安;邢丰
【期刊名称】《肿瘤药学》 【年(卷),期】2013(000)006
【摘要】Objective To discuss the short-term effects and hematologic adverse reactions in the treatment of advanced ma-lignant tumors with gemcitabine plus oxaliplatin. Methods Seventy-six patients with advanced malignant tumor treated in our hospital between Jan. 2010 and Dec. 2012 were randomly selected and divided into the single-agent gemcitabine treatment group (Monotherapy group ) and the gemcitabine and oxaliplatin treatment group (Combination group). After two cycles of chemo-therapy, the efficacy and hematologic adverse reactions in the two groups were compared and analyzed. Results The total remis-sion rate in the Combination group was 71.05%, higher than that of the monotherapy group (52.63%, P<0.05). However, the
hematologic
adverse
reactions
such
as
neutropenia,
thrombocytopenia and asphaerinia in the Combination group were also higher than that in the monotherapy group (P<0.05). Conclusion The combination of gemcitabine and oxaliplatin in the treatment for advanced malignant tumor can improve the shor term effects but could cause greater hematologic adverse reactions. It is necessary to pay
吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血液学不良反应观察
